Prashant R. Singh

This paper develops CRISPR-MACE, a platform for continuous directed evolution of CRISPR-Cas9 in human cells, generating variants with enhanced DNA binding and resistance to AcrIIA4.

This paper develops a small molecule, BRD8833, that induces BCR-ABL phosphorylation to disrupt its active site electric field, leading to loss of hyperactivity and apoptosis in BCR-ABL-dependent cancer cells.

This study identifies small molecule inhibitors of TOX protein that reverse T cell exhaustion and show cytotoxicity in T-ALL.